Home » Stocks » HGEN

Humanigen Inc. (HGEN)

Stock Price: $19.68 USD -0.38 (-1.89%)
Updated Jun 16, 2021 4:00 PM EDT - Market closed
After-hours: $19.47 -0.21 (-1.07%) Jun 16, 4:35 PM
Market Cap 1.16B
Revenue (ttm) 798,000
Net Income (ttm) -152.64M
Shares Out 52.66M
EPS (ttm) -3.44
PE Ratio n/a
Forward PE 12.38
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $19.68
Previous Close $20.06
Change ($) -0.38
Change (%) -1.89%
Day's Open 19.74
Day's Range 18.88 - 19.96
Day's Volume 987,965
52-Week Range 7.75 - 29.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced it has initiated a rolling review submission for Marketing Authorization (MA) by the MHRA for its lead drug candidate, lenzilumab

2 days ago - Business Wire

While vaccines and diagnostics have been the big winners in the space so far, Humanigen might make investors a lot of money with its drug to treat cytokine storms caused by COVID-19.

Other stocks mentioned: GSK, NVAX
5 days ago - The Motley Fool

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

1 week ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces it will present at the 2021 LD Micro Invitational XI

1 week ago - Business Wire

One is growing revenue. And the other may soon launch its first product.

Other stocks mentioned: EXEL
2 weeks ago - The Motley Fool

Humanigen Inc (NASDAQ: HGEN) has submitted an application to the FDA seeking Emergency Use Authorization (EUA) for lenzilumab to treat patients hospitalized with COVID-19. The application is based on po...

2 weeks ago - Benzinga

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces submission of application to the FDA requesting Emergency Use Authorization for lenzilumab

2 weeks ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces that granulocyte macrophage-colony stimulating factor gene-edited CAR-T data will be presented at the ISCT 2021 Annual Meeting

3 weeks ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

4 weeks ago - Business Wire

Humanigen Inc (NASDAQ: HGEN) and Chime Biologics, contract development and manufacturing organization (CDMO), have entered into a manufacturing services agreement to produce Humanigen's lenzilumab bulk ...

4 weeks ago - Benzinga

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen and Chime Biologics today announced that they have entered into a manufacturing services agreement.

4 weeks ago - Business Wire

Humanigen Inc (NASDAQ: HGEN) is prepping its COVID-19 drug lenzilumab for an emergency use authorization with the FDA before the month's end. According to its Q1 financial report out Thursday after-hour...

1 month ago - Benzinga

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. today reported financial results for the first quarter ending March 31, 2021 and provided a regulatory update on lenzilumab.

1 month ago - Business Wire

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

Humanigen Inc. (NASDAQ: HGEN) shares made gains Wednesday  following the publication of results from a Phase 3 randomized double-blind placebo-controlled study.

1 month ago - Benzinga

Detailed results from a late-stage study of the company's lead candidate were published online.

1 month ago - The Motley Fool

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

1 month ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced the appointment of Adrian Kilcoyne, MD, MBA, MPH, to the newly-created role of Chief Medical Officer.

1 month ago - Business Wire

They're both innovating in attractive areas where there's no competition on the radar.

Other stocks mentioned: EWTX
1 month ago - The Motley Fool

New coronavirus projects make them easy to hype, but they could face strong headwinds soon.

Other stocks mentioned: OCGN
1 month ago - The Motley Fool

Humanigen Inc (NASDAQ: HGEN) has announced data from the Phase 1b portion of the ZUMA-19 trial evaluating its lead candidate lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (D...

1 month ago - Benzinga

BURLINGAME, Calif.--(BUSINESS WIRE)--Positive data announced from the Phase 1b portion of ZUMA-19 evaluating the efficacy and safety of lenzilumab in patients treated with CAR-T in DLBCL.

1 month ago - Business Wire

They're approaching the treatment-race finish line.

Other stocks mentioned: RDHL
2 months ago - The Motley Fool

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Humanigen Inc (NASDAQ: HGEN) has announced results from the Phase 1 trial evaluating its second Humaneered antibody, ifabotuzumab, in patients with glioblastoma multiforme (GBM), the most frequent and l...

2 months ago - Benzinga

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces positive results from the Phase 1 safety and bioimaging trial of ifabotuzumab.

2 months ago - Business Wire

It's a definite maybe.

2 months ago - The Motley Fool

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced it completed its underwritten public offering of common stock.

2 months ago - Business Wire

The company announced the pricing of a secondary stock offering.

2 months ago - The Motley Fool

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called “cytokine ...

2 months ago - Business Wire

Humanigen Inc. (NASDAQ: HGEN) share rallied Monday amid positive Phase 3 data demonstrating Lenzilumab TM achieved its primary endpoint. The drug improves survival without the need for mechanical ventil...

2 months ago - Benzinga

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announced that it has commenced an underwritten public offering 5,000,000 shares of its common stock.

2 months ago - Business Wire

The company's investigational coronavirus treatment could hit the market soon.

2 months ago - The Motley Fool

Shares of HGEN stock are soaring after the firm said its drug results show improved survival for Covid-19 patients without a ventilator. The post HGEN Stock: Why Covid-19 Play Humanigen Is Skyrocketing ...

2 months ago - InvestorPlace

Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.

Other stocks mentioned: BLUE, QURE, AMPH
2 months ago - Benzinga

Humanigen Inc (NASDAQ: HGEN) has reported topline data from Phase 3 study evaluating its lead drug candidate, lenzilumab, in patients hospitalized with COVID-19. The 520-patient study demonstrated that ...

2 months ago - Benzinga

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces positive topline results from its Phase 3 clinical trial.

2 months ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

2 months ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. announced today that its board of directors has scheduled the corporation's 2021 Annual Meeting of Shareholders for June 17, 2021.

2 months ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. has obtained a term loan facility from Hercules Capital.

3 months ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. reports financial results for the year ending December 31, 2020 and announces objectives for 2021.

3 months ago - Business Wire

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

3 months ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen awarded two patents, expanding their anti-GM-CSF patent portfolio.

3 months ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

3 months ago - Business Wire

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

Other stocks mentioned: AIM, CDMO, CYDY, FLGT, JAGX, PRTC
3 months ago - InvestorPlace

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine...

4 months ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen announces the election of Dr. Dale Chappell, the Company's chief scientific officer, to serve as a board director of the Company.

4 months ago - Business Wire

BURLINGAME, Calif. & TUSTIN, Calif.--(BUSINESS WIRE)--Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) (“Avid”) and Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”) today announced that they have entered ...

Other stocks mentioned: CDMO, CDMOP
4 months ago - Business Wire

BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc. (NASDAQ:HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine s...

4 months ago - Business Wire

About HGEN

Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies t... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2013
CEO
Cameron Durrant
Employees
10
Stock Exchange
NASDAQ
Ticker Symbol
HGEN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Humanigen stock is "Buy." The 12-month stock price forecast is 34.88, which is an increase of 77.24% from the latest price.

Price Target
$34.88
(77.24% upside)
Analyst Consensus: Buy